TY  - GEN
AU  - Efstathiou,E
AU  - Bozas,G
AU  - Kostakopoulos,A
AU  - Kastritis,E
AU  - Deliveliotis,C
AU  - Antoniou,N
AU  - Skarlos,D
AU  - Papadimitriou,C
AU  - Dimopoulos,M A
AU  - Bamias,A
TI  - Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
SN  - 1527-9995
PY  - 2005///0919
KW  - Adenocarcinoma
KW  - blood
KW  - Aged
KW  - Aged, 80 and over
KW  - Alopecia
KW  - chemically induced
KW  - Androgen Antagonists
KW  - therapeutic use
KW  - Antineoplastic Agents, Hormonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers, Tumor
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Combined Modality Therapy
KW  - Diphosphonates
KW  - administration & dosage
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Drug Resistance, Neoplasm
KW  - Estramustine
KW  - Humans
KW  - Imidazoles
KW  - Life Tables
KW  - Liver Neoplasms
KW  - Lung Neoplasms
KW  - Lymphatic Metastasis
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Proteins
KW  - Neutropenia
KW  - Orchiectomy
KW  - Pain
KW  - Palliative Care
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms
KW  - Radiotherapy, High-Energy
KW  - Remission Induction
KW  - Survival Analysis
KW  - Taxoids
KW  - Treatment Outcome
KW  - Zoledronic Acid
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1016/j.urology.2004.08.041
ER  -